Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A look at outcomes with VeriStrat
May 2019
SHARING OPTIONS:

BOULDER, Colo. & SAN DIEGO—At the recent Multidisciplinary Thoracic Cancers Symposium, Biodesix shared new front-line data showing that its VeriStrat test can predict outcomes for non-small cell lung cancer (NSCLC) patients who have been treated with immune checkpoint inhibitors in the first-line setting, even when adjusted to PD-L1 status. The data come from a prospectively designed observational study that will follow patient outcomes for 18 months, with an interim analysis conducted with the first 1,000 patients enrolled with at least 12 months of follow up. Patients who were identified as VeriStrat Poor saw significantly lower overall survival with any immune checkpoint inhibitor-based regimen compared to those identified as VeriStrat Good. A VeriStrat Good result also indicated significantly higher median overall survival for both immuno-monotherapy and immunotherapy with chemotherapy.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.